Unlocking the future of medicine
Australia’s only CDMO providing complete life cycle viral vector services to the global cell and gene therapy sector.
Why global biotechs choose VVMF for their viral vector manufacturing
VVMF gives biotechs confidence when moving from development to GMP production
Scientific depth and accountable delivery
Our team brings deep viral vector expertise, strong links to Australia’s advanced therapies ecosystem, and a committed, collaborative way of working.
We partner closely with clients to understand their program, manage technical risk and define the right development path.
Flexible, modern manufacturing
Our single-use technologies and platform-based approach support efficient development, scale-up, and cGMP manufacturing.
Through active technology partnerships, we combine proven bioprocessing solutions with the flexibility to tailor each program where needed.
The Australian Advantage
Manufacturing in Australia offers clients access to a strong clinical research environment and potential R&D Tax Incentive benefits for eligible activities.
VVMF helps clients use this advantage to support efficient, cost-effective progression toward clinical and commercial milestones.
The Australian advantage
Progress to Clinic Faster
Australia offers emerging CGT biopharma companies a globally competitive pathway for viral vector development and GMP manufacturing. Australia’s unique advantages help companies progress to clinic faster, reduce development risk and achieve greater capital efficiency.
- 01Capital-efficient development is supported by Australia’s attractive R&D Tax Incentive, helping eligible companies make development capital go further.
- 02Regulatory confidence and speed, with a globally recognised regulatory framework and mature clinical trial ecosystem supporting an efficient pathway to early-phase clinical trials
- 03Strategic APAC location provides a stable, well-connected base in the Asia-Pacific region, supported by strong intellectual property protection.
- 04World-class scientific expertise, with globally recognised capabilities across viral vectors, cell and gene therapies, and clinical research.
Your partner for viral vector development and manufacturing
our capabilities
End-to-end viral vector CDMO capabilities
From vector design to GMP manufacture and release, VVMF supports viral vector programs with integrated scientific, process, manufacturing, and quality capabilities.
R&D and Vector Candidate Discovery
R&D and Vector Candidate Discovery
Early-stage support for vector design, plasmid sourcing and cell banking, helping clients select and prepare candidates with manufacturability, performance, and clinical translation in mind.
Process and Analytical Development
Process and Analytical Development
Scalable process development, analytical methods, Quality by Design, and Design of Experiments approaches to build process understanding, improve performance and support GMP readiness.
Industrialisation and Manufacturing
Industrialisation and Manufacturing
Flexible manufacturing and fill-finish solutions designed to translate development processes into reliable, traceable, and phase-appropriate GMP production.
Quality Control and Assurance
Quality Control and Assurance
Comprehensive QC testing, release documentation, and quality oversight to support regulatory confidence and clinical or commercial material supply.
AAV and LV vector platforms to make viral vector manufacturing faster, more robust and cost-effective.
As viral vector-based therapies expand into cancer, chronic disease, and autoimmune indications, developers need faster, simpler pathways from development through to scalable manufacturing. VVMF supports this need through platformised, ready-to-use solutions that integrate upstream production, downstream purification, quality control, and analytical testing.
Built around optimised HEK-293 suspension cell systems, our transient expression platforms are designed to reduce development complexity, shorten production lead times, and improve manufacturing consistency. With only targeted process fine-tuning required, clients can lock processes faster and scale production more efficiently.
Adeno-Associated Virus (AAV)
Scalable AAV production using optimised HEK-293 suspension systems up to 500L, transient triple or dual transfection, platform purification based on affinity and ion exchange chromatography, and integrated analytics to accelerate development and GMP translation.
Lentivirus (LV)
Robust VSV-G lentiviral vector production through scalable HEK-293 suspension workflows, optimised upstream up to various bioreactor volumes, downstream processing, and phase-appropriate analytical control designed for ex-vivo CAR-T applications.
Bespoke
For products with unique requirements, VVMF applies its platform knowledge, development toolbox, and analytical capabilities to design and optimise tailored manufacturing solutions.
When a product does not fit a standard platform workflow, VVMF applies its bioprocessing toolbox to build a tailored development path.
Our bespoke services can support construct or vector-specific requirements across upstream processing, downstream purification, analytics, formulation, scale-up, technology transfer and GMP readiness.
This allows clients to retain the speed and structure of VVMF’s platform knowledge while addressing the specific needs of their therapy.
Latest News
Viral Vector Manufacturing Facility (VVMF) and Peter MacCallum CancerCentre (Peter Mac) sign Letter of Intent to advance novel CAR T-celltherapy with potential in multiple myeloma, solid tumours
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s only commercial viral vector Contract Development and Manufacturing Organisation (CDMO) and Peter
Viral Vector Manufacturing Facility (VVMF) has been named one of Australia’s Best Workplaces™ in Biotechnology and Pharmaceutical 2026
Great Place To Work®, the global authority on workplace culture, has today announced that Viral Vector Manufacturing Facility Pty Ltd (VVMF) has been